Perion Network Sees Upbeat Q2 Revenue; FDA's FTD Boosts Kazia
- July 06th, 2023
- 330 views
Perion Network Ltd. (Nasdaq: PERI) has released its preliminary results, revealing an anticipated second-quarter 2023 revenue of $176 million, marking a 20% year-over-year increase. This projection surpasses the consensus estimate of $169.88 million for the period.
In pre-market trading, $PERI was observed at $33.18, reflecting a notable rise of $2.30 (7.45%).
In other news, Kazia Therapeutics Limited (Nasdaq: KZIA) has obtained Fast Track Designation (FTD) from the FDA for its drug paxalisib, intended for the treatment of solid tumor brain metastases with PI3K pathway mutations in conjunction with radiation therapy.
FTD aims to accelerate the development of pharmaceutical products addressing unmet medical needs, granting Kazia enhanced access to the FDA, including accelerated approval and priority review possibilities, potentially facilitating faster product approval.
$KZIA was trading at $1.52 in pre-market, up $0.35 (29.91%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login